Chugai Pharmaceutical Co. (CHGCY)
(Delayed Data from OTC)
$24.98 USD
+0.81 (3.35%)
Updated Aug 23, 2024 03:59 PM ET
2-Buy of 5 2
B Value B Growth C Momentum B VGM
Income Statements
Fiscal Year end for Chugai Pharmaceutical Co, Ltd Unsponsored ADR falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 7,891 | 9,702 | 9,098 | 7,397 | 6,313 |
Cost Of Goods | 2,934 | 3,667 | 3,077 | 2,571 | 2,448 |
Gross Profit | 4,956 | 6,034 | 6,021 | 4,827 | 3,865 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,838 | 1,928 | 2,181 | 1,995 | 1,928 |
Income After Depreciation & Amortization | 3,118 | 4,106 | 3,839 | 2,832 | 1,937 |
Non-Operating Income | 33 | -16 | -22 | -28 | -24 |
Interest Expense | 0 | 0 | 0 | 1 | 1 |
Pretax Income | 3,151 | 4,090 | 3,816 | 2,803 | 1,913 |
Income Taxes | 840 | 1,207 | 1,059 | 784 | 463 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 2,311 | 2,883 | 2,757 | 2,018 | 1,450 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 2,311 | 2,883 | 2,757 | 2,018 | 1,450 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 3,118 | 4,349 | 4,120 | 3,117 | 2,180 |
Depreciation & Amortization (Cash Flow) | NA | 242 | 281 | 286 | 243 |
Income After Depreciation & Amortization | 3,118 | 4,106 | 3,839 | 2,832 | 1,937 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 3,290.92 | 3,290.67 | 3,290.46 | NA | NA |
Diluted EPS Before Non-Recurring Items | 0.71 | 0.87 | 0.84 | NA | NA |
Diluted Net EPS (GAAP) | 0.70 | 0.88 | 0.84 | 0.61 | 1.32 |
Fiscal Year end for Chugai Pharmaceutical Co, Ltd Unsponsored ADR falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 2,026.48 | 1,596.56 | 1,854.26 | 1,784.91 | 1,948.40 |
Cost Of Goods | NA | NA | NA | NA | NA |
Gross Profit | NA | NA | NA | NA | NA |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Non-Operating Income | NA | NA | NA | NA | NA |
Interest Expense | NA | NA | NA | NA | NA |
Pretax Income | NA | NA | NA | NA | NA |
Income Taxes | NA | NA | NA | NA | NA |
Minority Interest | NA | NA | NA | NA | NA |
Investment Gains/Losses | NA | NA | NA | NA | NA |
Other Income/Charges | NA | NA | NA | NA | NA |
Income From Cont. Operations | 717.56 | 501.31 | 617.65 | 536.88 | 606.14 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 717.56 | 501.31 | 617.65 | 536.88 | 606.14 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 3,290.79 | 3,291.35 | 3,290.85 | 3,290.48 | 3,290.86 |
Diluted EPS Before Non-Recurring Items | 0.22 | 0.15 | 0.19 | 0.16 | 0.18 |
Diluted Net EPS (GAAP) | 0.22 | 0.15 | 0.19 | 0.16 | 0.18 |